Status:

SUSPENDED

Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma

Lead Sponsor:

Shanghai Jiao Tong University School of Medicine

Conditions:

Multiple Myeloma

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

The clinical trial is to evaluate the efficacy of single autologous hematopoietic stem cell transplantation with standard conditioning of melphalan 200 mg/m2 followed by thalidomide maintenance in pat...

Detailed Description

This is an open label clinical trial to evaluate the efficacy of single autologous hematopoietic stem cell transplantation in newly diagnosed multiple myeloma patients. All patients will receive 4-6 c...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Man or woman between age 18-65 with newly diagnosed Multiple Myeloma for whom stem cell transplantation is considered appropriate
  • Measurable serum and/or urinary paraprotein
  • European Cooperative Oncology Group performance status 0-3
  • Serum bilirubin \< 1.5x the upper limit of normal (ULN)
  • Serum alanine transaminase (ALT)/aspartate transaminase values \< 2.5 x ULN
  • Subjects (or their legally acceptable representatives) must signed an informed consent document indicating that they understanding the purpose of and procedures required for the study and are willing to participate in the study
  • Exclusion criteria:
  • Woman of child bearing potential
  • Non-secretory MM
  • Serum creatinine \> 400 Micromol/l after initial resuscitation
  • patients with previous Grade 2-4 peripheral neuropathy
  • Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
  • Uncontrolled or severe cardiovascular disease including myocardial infarction within 6 months of enrollment, uncontrolled angina, clinically significant pericardial disease, or III-IV heart failure

Exclusion

    Key Trial Info

    Start Date :

    May 1 2009

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2017

    Estimated Enrollment :

    80 Patients enrolled

    Trial Details

    Trial ID

    NCT00892346

    Start Date

    May 1 2009

    End Date

    December 1 2017

    Last Update

    May 10 2016

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Rui Jin Hospital, Shanghai JiaoTong University School of Medicine

    Shanghai, China, 200025